Close

Stifel Positive on Vertex (VRTX) as Triple Combo Moves Forward; PT Trimmed to $108

Go back to Stifel Positive on Vertex (VRTX) as Triple Combo Moves Forward; PT Trimmed to $108

Jefferies Reiterates Buy on Vertex Pharma (VRTX) Following Investor Event

October 28, 2016 7:54 AM EDT

Jefferies reiterated a Buy rating and $102.00 price target on Vertex Pharma (NASDAQ: VRTX) following an investor event. Jefferies thought VRTX made a good argument for the viability of their next-gen correctors despite some questions raised about their safety profiles. They pointed out that while the teratogenicity with '440... More

Vertex Pharma (VRTX): Cutting PT But Fundamentals Continue To Look Good - Jefferies

October 26, 2016 8:39 AM EDT

Jefferies analyst, Brian Abrahams, reiterated his Buy rating on shares of Vertex (NASDAQ: VRTX) but cut his price target to $102 from $105 based on changes to the analyst's DCF.

For the quarter, numbers were in line, but 3Q was highlighted by both next-gen correctors,... More

Vertex Pharma (VRTX): Many Shots on Goal But Uncertain Safety Limits Upside - Leerink

October 26, 2016 7:02 AM EDT

Leerink Partners analyst, Geoffrey Porges, reiterated his Outperform rating on shares of Vertex (NASDAQ: VRTX) but cut his price target to $111 from $112 after the company reported Q3 results but, more importantly, disclosed their long anticipated phase II development plans for their triple combination for the... More

Vertex (VRTX) PT Bumped to $88 at BMO Capital Following Results and Triple Combo Update

October 26, 2016 6:51 AM EDT

BMO Capital analyst Do Kim bumped his price target on Vertex (NASDAQ: VRTX) to $88.00 (from $87.00) following results and the triple combo update but maintained a Market Perform rating.

Kim commented, " Vertex's 3Q16 was generally in line with expectations, as prior comments and revised... More

Vertex Pharma (VRTX) Misses Q3 EPS by 2c; Plans to Commence Two CF-Focused Phase 2s

October 25, 2016 4:04 PM EDT

Vertex Pharma (NASDAQ: VRTX) reported Q3 EPS of $0.16, $0.02 worse than the analyst estimate of $0.18. Revenue for the quarter came in at $410 million versus the consensus estimate of $418.37 million.

Vertex also announced the planned initiation of two Phase 2 studies to evaluate the next-generation correctors VX-440 and VX-152 in triple combination regimens with tezacaftor (VX-661) and ivacaftor in people with cystic fibrosis (CF). The Phase 2 study of VX-440 is designed to evaluate the safety and efficacy of 4-week dosing of VX-440 in combination with tezacaftor and ivacaftor in approximately 40 people with CF who... More